Medindia LOGIN REGISTER
Medindia
Advertisement

Clouded Future for Merck's Blood Thinning Drug Vorapaxar

by Dr. Trupti Shirole on March 25, 2012 at 6:18 PM
 Clouded Future for Merck's Blood Thinning Drug Vorapaxar

Merck & Co.'s experimental anti-platelet drug vorapaxar reduces the risk of heart attacks but increases the risk of significant bleeding.

The latest studies have raised questions whether the company will seek approval for the drug from the U.S. Food and Drug Administration.

Advertisement

From January 2011 a safety committee overseeing the 26,449-patient study had questioned its efficacy as they found that the new type of anti-platelet drug was not appropriate for patients who had suffered a stroke, due to bleeding risk.

Source: Medindia
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Clouded Future for Merck's Blood Thinning Drug Vorapaxar Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests